Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report.


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
20 09 2023
Historique:
pmc-release: 20 09 2024
medline: 18 9 2023
pubmed: 17 7 2023
entrez: 17 7 2023
Statut: ppublish

Résumé

Chemotherapeutic exposures are associated with subsequent malignant neoplasm (SMN) risk. The role of genetic susceptibility in chemotherapy-related SMNs should be defined as use of radiation therapy (RT) decreases. SMNs among long-term childhood cancer survivors of European (EUR; N = 9,895) and African (AFR; N = 718) genetic ancestry from the Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study were evaluated. An externally validated 179-variant polygenic risk score (PRS) associated with pleiotropic adult cancer risk from the UK Biobank Study (N > 400,000) was computed for each survivor. SMN cumulative incidence comparing top and bottom PRS quintiles was estimated, along with hazard ratios (HRs) from proportional hazards models. A total of 1,594 survivors developed SMNs, with basal cell carcinomas (n = 822), breast cancers (n = 235), and thyroid cancers (n = 221) being the most frequent. Although SMN risk associations with the PRS were extremely modest in RT-exposed EUR survivors (HR, 1.22; A pleiotropic cancer PRS has strong potential for improving SMN clinical risk stratification among nonirradiated survivors treated with specific chemotherapies. A polygenic risk screening approach may be a valuable complement to an early screening strategy on the basis of treatments and rare cancer-susceptibility mutations.

Identifiants

pubmed: 37459583
doi: 10.1200/JCO.23.00428
pmc: PMC10522108
doi:

Substances chimiques

Podophyllotoxin L36H50F353

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4381-4393

Subventions

Organisme : NCI NIH HHS
ID : U24 CA055727
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA261833
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA195547
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA216354
Pays : United States

Références

Nat Commun. 2020 Nov 27;11(1):6084
pubmed: 33247094
Clin Cancer Res. 2019 Nov 15;25(22):6700-6708
pubmed: 31462438
Radiat Res. 2019 Aug;192(2):169-188
pubmed: 31211642
Nat Commun. 2020 Feb 10;11(1):820
pubmed: 32041948
J Clin Oncol. 2018 Aug 20;36(24):2504-2513
pubmed: 29989856
N Engl J Med. 2016 Mar 3;374(9):833-42
pubmed: 26761625
Pediatr Blood Cancer. 2012 Mar;58(3):334-43
pubmed: 22038641
Nat Genet. 2017 May;49(5):680-691
pubmed: 28346442
J Clin Oncol. 2017 Jul 10;35(20):2288-2298
pubmed: 28530852
J Clin Oncol. 2016 Mar 20;34(9):910-8
pubmed: 26700127
Clin Cancer Res. 2018 Dec 15;24(24):6230-6235
pubmed: 30366939
Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2096-2104
pubmed: 34465587
Nat Commun. 2017 Feb 14;8:14517
pubmed: 28195142
J Natl Cancer Inst. 2001 Apr 18;93(8):618-29
pubmed: 11309438
Pediatr Blood Cancer. 2014 Jan;61(1):53-67
pubmed: 23940101
Biometrics. 2005 Mar;61(1):92-105
pubmed: 15737082
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059430
Med Pediatr Oncol. 2002 Apr;38(4):229-39
pubmed: 11920786
Am J Hum Genet. 2020 Oct 1;107(4):636-653
pubmed: 32946765
Am J Hum Genet. 2020 Nov 5;107(5):815-836
pubmed: 32991828
J Clin Oncol. 2006 Jan 20;24(3):476-83
pubmed: 16421424
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
J Clin Oncol. 2013 Oct 20;31(30):3807-14
pubmed: 24043737
PLoS Genet. 2019 Jun 13;15(6):e1008202
pubmed: 31194742
Nat Genet. 2014 Nov;46(11):1233-8
pubmed: 25261932
Nat Genet. 2021 Jan;53(1):65-75
pubmed: 33398198
Hum Mol Genet. 2019 Sep 15;28(18):3148-3160
pubmed: 31174203
Cancer Causes Control. 2000 Jul;11(6):477-88
pubmed: 10880030
J Clin Oncol. 2009 May 10;27(14):2308-18
pubmed: 19364948
Pediatr Blood Cancer. 2013 Jul;60(7):1083-94
pubmed: 23418018
J Natl Cancer Inst. 1989 Oct 4;81(19):1464-71
pubmed: 2674459
Am J Epidemiol. 1997 Jan 1;145(1):72-80
pubmed: 8982025
J Invest Dermatol. 2019 Sep;139(9):2042-2045.e8
pubmed: 30910758
Nat Commun. 2017 Jul 13;8:15966
pubmed: 28703219
J Clin Oncol. 1994 Oct;12(10):2066-70
pubmed: 7931475
J Clin Oncol. 2019 Dec 1;37(34):3310-3319
pubmed: 31622130
J Clin Epidemiol. 2004 Apr;57(4):332-40
pubmed: 15135833
J Clin Oncol. 2018 Jul 10;36(20):2078-2087
pubmed: 29847298
JAMA. 2011 Jun 8;305(22):2311-9
pubmed: 21642683
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):224-30
pubmed: 22795729
BMJ. 1992 Apr 11;304(6832):951-8
pubmed: 1581717
J Natl Cancer Inst. 2010 Jul 21;102(14):1083-95
pubmed: 20634481
J Clin Oncol. 2009 May 10;27(14):2319-27
pubmed: 19364957
Nat Commun. 2016 Aug 19;7:12510
pubmed: 27539887
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Nat Genet. 2020 Jun;52(6):572-581
pubmed: 32424353
Nat Commun. 2020 Sep 4;11(1):4423
pubmed: 32887889
JAMA Oncol. 2019 Jun 01;5(6):864-871
pubmed: 30703192
Nat Genet. 2018 Sep;50(9):1219-1224
pubmed: 30104762
J Clin Oncol. 2018 Jul 20;36(21):2145-2152
pubmed: 29874133
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
JAMA Oncol. 2016 Dec 01;2(12):1624-1627
pubmed: 27711914
Nat Commun. 2016 Jul 18;7:12048
pubmed: 27424798
N Engl J Med. 1991 Dec 12;325(24):1682-7
pubmed: 1944468
JCO Precis Oncol. 2020 Aug 21;4:
pubmed: 32923912
JAMA. 2017 Feb 28;317(8):814-824
pubmed: 28245323
Ann Intern Med. 2012 Jun 5;156(11):757-66, W-260
pubmed: 22665813
Nat Genet. 2017 May;49(5):789-794
pubmed: 28346443
Cancer Res. 2022 Aug 16;82(16):2940-2950
pubmed: 35713625
J Natl Cancer Inst. 2007 Feb 21;99(4):300-8
pubmed: 17312307
J Clin Oncol. 2012 Jul 10;30(20):2552-8
pubmed: 22665546
J Clin Oncol. 2011 Aug 1;29(22):3056-64
pubmed: 21709189
Genet Epidemiol. 2017 Sep;41(6):469-480
pubmed: 28480976
Nat Protoc. 2020 Sep;15(9):2759-2772
pubmed: 32709988
Cancer Res. 2020 Sep 1;80(17):3755-3764
pubmed: 32554749
Nat Commun. 2018 Sep 13;9(1):3707
pubmed: 30213928
Int J Epidemiol. 2021 Mar 3;50(1):39-49
pubmed: 33374007
Nat Genet. 2022 Aug;54(8):1167-1177
pubmed: 35915169

Auteurs

Cindy Im (C)

Department of Pediatrics, University of Minnesota, Minneapolis, MN.

Noha Sharafeldin (N)

Hematology Oncology Division, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.

Yan Yuan (Y)

School of Public Health, University of Alberta, Edmonton, Alberta, Canada.

Zhaoming Wang (Z)

Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.
Department of Computational Biology, St Jude Children's Research Hospital, Memphis, TN.

Yadav Sapkota (Y)

Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.

Zhanni Lu (Z)

Department of Pediatrics, University of Minnesota, Minneapolis, MN.

Logan G Spector (LG)

Department of Pediatrics, University of Minnesota, Minneapolis, MN.

Rebecca M Howell (RM)

Department of Radiation Physics, University of Texas at MD Anderson Cancer Center, Houston, TX.

Michael A Arnold (MA)

Department of Pathology and Laboratory Medicine, University of Colorado and Children's Hospital Colorado, Anschutz Medical Campus, Aurora, CO.

Melissa M Hudson (MM)

Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.
Department of Oncology, St Jude Children's Research Hospital, Memphis, TN.

Kirsten K Ness (KK)

Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.

Leslie L Robison (LL)

Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.

Smita Bhatia (S)

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL.

Gregory T Armstrong (GT)

Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.
Department of Oncology, St Jude Children's Research Hospital, Memphis, TN.

Joseph P Neglia (JP)

Department of Pediatrics, University of Minnesota, Minneapolis, MN.

Yutaka Yasui (Y)

School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN.

Lucie M Turcotte (LM)

Department of Pediatrics, University of Minnesota, Minneapolis, MN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH